Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Other financing activities (2020 - 2025)

Historic Other financing activities for Maravai Lifesciences Holdings (MRVI) over the last 4 years, with Q1 2025 value amounting to $1.4 million.

  • Maravai Lifesciences Holdings' Other financing activities fell 4217.83% to $1.4 million in Q1 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 6164.09%. This contributed to the annual value of $9.3 million for FY2024, which is 5056.74% up from last year.
  • Maravai Lifesciences Holdings' Other financing activities amounted to $1.4 million in Q1 2025, which was down 4217.83% from $2.2 million recorded in Q4 2024.
  • Maravai Lifesciences Holdings' 5-year Other financing activities high stood at $2.4 million for Q1 2024, and its period low was $492000.0 during Q1 2023.
  • In the last 3 years, Maravai Lifesciences Holdings' Other financing activities had a median value of $2.2 million in 2024 and averaged $1.9 million.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Other financing activities surged by 38333.33% in 2024, and later plummeted by 4217.83% in 2025.
  • Quarter analysis of 3 years shows Maravai Lifesciences Holdings' Other financing activities stood at $2.3 million in 2023, then fell by 4.22% to $2.2 million in 2024, then tumbled by 38.2% to $1.4 million in 2025.
  • Its Other financing activities was $1.4 million in Q1 2025, compared to $2.2 million in Q4 2024 and $2.3 million in Q3 2024.